Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• Age ≥ 18 years.
• Histopathology or cytology confirmed lung cancer
• Failed from first line Chemo-immunotherapy.
• ECOG 0-1.
• Predicted survival ≥ 12 weeks.
• Adequate bone marrow hematopoiesis and organ function
• Presence of measurable lesions according to RECIST 1.1.
• Subjects with stable brain metastases may be included in the study.
Locations
Other Locations
China
Yongchang Zhang
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Time Frame
Start Date: 2020-03-24
Estimated Completion Date: 2029-03-24
Participants
Target number of participants: 1200
Treatments
Experimental: Cohort A: Anlotinib with the same Immune Checkpoint Inhibitors.
Anlotinib plus Immune Checkpoint Inhibitors which has been used in first line treatment.
Experimental: Cohort B: Anlotinib with the new Immune Checkpoint Inhibitors.
Anlotinib plus Immune Checkpoint Inhibitors which has not been used in first line treatment.
Experimental: Cohort C: Anlotinib Monotherapy.
Anlotinib Monotherapy.
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital